Post
Ochre Bio and Boehringer enter CLD regenerative therapy deal
Ochre Bio has entered a strategic collaboration with Boehringer Ingelheim to discover and develop new regenerative treatments for treating chronic …
ImmunityBio’s ANKTIVA receives FDA approval for bladder cancer
The US Food and Drug Administration (FDA) has granted approval for ImmunityBio's ANKTIVA, plus Bacillus Calmette-Guérin (BCG), for treating patients …
Ipsen and Skyhawk partner to develop rare neurological therapies
Ipsen has entered an exclusive global collaboration with Skyhawk Therapeutics for the discovery and development of new small molecules that …
EC approves Pfizer’s Emblaveo for multidrug-resistant infections
The European Commission (EC) has granted marketing authorisation for Pfizer’s Emblaveo (aztreonam-avibactam), aimed at treating adults with multidrug-resistant infections where …
Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval
Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase …
AlphaMedix by Orano Med for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
AlphaMedix is under clinical development by Orano Med and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to …
Lorcaserin hydrochloride by EpyGenix Therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Likelihood of Approval
Lorcaserin hydrochloride is under clinical development by EpyGenix Therapeutics and currently in Phase I for Dravet Syndrome (Severe Myoclonic Epilepsy …
Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. …
Datopotamab deruxtecan by Daiichi Sankyo for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Head And Neck Squamous Cell …
Datopotamab deruxtecan by Daiichi Sankyo for Epithelial Ovarian Cancer: Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Epithelial Ovarian Cancer. According to …
Datopotamab deruxtecan by Daiichi Sankyo for Peritoneal Cancer: Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Peritoneal Cancer. According to GlobalData, …
Datopotamab deruxtecan by Daiichi Sankyo for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell …
Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Ovarian Cancer: Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Ovarian Cancer. According to …
Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Colorectal Cancer: Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Metastatic Colorectal Cancer. According to …
Datopotamab deruxtecan by Daiichi Sankyo for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Non Muscle Invasive Bladder Cancer …